Articles

Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than durable polymer DES, according to findings from an analysis of three major clinical trials — ISAR-...

April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting stent (DES). Ten years ago, the mood surrounding the new anti-restinotic silver bullet stent was one of...

A U.S. Food and Drug Administration (FDA) review panel has given its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts...

The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive, percutaneous coronary interventions (PCI) procedures can perform as well or...

Abbott began enrolling U.S. patients in the EXCEL trial, which will compare the use of the Xience Prime or Xience V drug-eluting strents to coronary artery bypass graft (CABG) surgery for...

There have been several key news items from the U.S. stent market over the past year. These include the introduction of several new stents, Cordis pulling out of the market, an expanded indication...

A drug-eluting, self-expanding stent that does not use a drug-carrier polymer is before the U.S. Food and Drug Administration (FDA) final pre-market approval (PMA) review and a decision is...

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on the horizon, which will utilize new platforms and alloys and present novel...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...